All information is correct at time of printing and is subject to change without notice. The Devon Formulary and Referral Website is not in any way liable for the accuracy of any information printed and stored by users. For the most up-to-date information, please refer to the website.
September 2023: Update to insulins
News
September 2023: Update to insulins
Two biosimilar insulins have been added to the Devon Formulary. These are cost saving compared to the originator insulins. All insulins should be prescribed by brand.
- Trurapi (biosimilar insulin aspart) has been added to the Devon Formulary as a green (first line) option. Trurapi is recommended for new patients requiring insulin aspart. If the patient requires an alternative device, refer to NovoRapid.
- NovoRapid (insulin aspart) is an option for existing patients and patients who require a NovoRapid device. For other patients requiring insulin aspart, Trurapi is recommended.
- Admelog (biosimilar insulin lispro) has been added to the Devon Formulary as a green (first line) option. Admelog is recommended for new patients requiring insulin lispro. If the patient requires an alternative device, refer to Humalog.
- Humalog (insulin lispro) is an option for existing patients who require a Humalog device. For other patients requiring insulin lispro, Admelog is recommended.
Lantus (insulin glargine) has been reclassified from blue (second line) to green (first line) as Lantus is now similar in price to the biosimilar Abasaglar and accounts for the majority of prescribing of insulin glargine in primary care in Devon.
Short-acting soluble insulins have been reclassified from green (first line) to blue (second line).
Pens for insulin cartridges have been added for North & East Devon to align with South & West Devon. This section has been updated to include pens for Trurapi and Admelog cartridges.
Click here for the formulary entry for insulins and pens for insulin cartridges.
See here for other updates to the formulary.
